Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Collaborator: Profil GmbH, Neuss, Germany
• Treatments: Insulin; Lixisenatide

Criteria

Inclusion Criteria:

• Male and female subjects with type 2 diabetes mellitus on diet and exercise with/without metformin

• HbA1c>=6,0 % and <=8,5 % at screening

• BMI 25 to 35 kg/m²

• 155>=BP systolic >=90 mmHg

• 100>=BP diastolic>=45 mmHg

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.